A role for ceramide in driving cancer cell resistance to doxorubicin. - Wikidata - awgldk - TriplyDB

A role for ceramide in driving cancer cell resistance to doxorubicin.

A role for ceramide in driving cancer cell resistance to doxorubicin.

http://www.wikidata.org/entity/Q40017408

about

Ceramide stimulates ABCA12 expression via peroxisome proliferator-activated receptor {delta} in human keratinocytes Evolving concepts in cancer therapy through targeting sphingolipid metabolism A review of ceramide analogs as potential anticancer agents Galactosylceramide affects tumorigenic and metastatic properties of breast cancer cells as an anti-apoptotic molecule A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis Emerging targets in lipid-based therapy Re-configuration of sphingolipid metabolism by oncogenic transformation.Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthase.Incorporation of Fluorescence Ceramide-Based HPLC Assay for Rapidly and Efficiently Assessing Glucosylceramide Synthase In Vivo.Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy.Ceramides stimulate caspase-14 expression in human keratinocytes.Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.Doxorubicin, DNA torsion, and chromatin dynamics.Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells Biological activities of fusarochromanone: a potent anti-cancer agent Ceramide modulates pre-mRNA splicing to restore the expression of wild-type tumor suppressor p53 in deletion-mutant cancer cells.Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival Doxorubicin influences the expression of glucosylceramide synthase in invasive ductal breast cancer Human glycolipid transfer protein gene (GLTP) expression is regulated by Sp1 and Sp3: involvement of the bioactive sphingolipid ceramide New Insights on Glucosylceramide Synthase in Cancer Drug Resistance and Myelosuppression.Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.Multiplex analysis of sphingolipids using amine-reactive tags (iTRAQ)HIF-1α depletion results in SP1-mediated cell cycle disruption and alters the cellular response to chemotherapeutic drugs.P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer.Autophagy induced by deficiency of sphingosine-1-phosphate phosphohydrolase 1 is switched to apoptosis by calpain-mediated autophagy-related gene 5 (Atg5) cleavage The combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma.Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES).The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.Ceramide glycosylation by glucosylceramide synthase selectively maintains the properties of breast cancer stem cells.Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1.DNA damage induces down-regulation of UDP-glucose ceramide glucosyltransferase, increases ceramide levels and triggers apoptosis in p53-deficient cancer cells.Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis.RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance.Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.

P2860

Q24651375-F7F421A2-29C4-44ED-B7C4-AB728970BB2F Q26863646-C855AD60-E349-432A-9284-E22C8F709EC9 Q27009351-97DD7370-B4E6-4027-86A9-0134F0229A14 Q27335599-05B88170-B1D9-4BB0-A044-AA3A90248D3E Q28476087-7E6CCA47-2244-4D9B-95E3-F7AA92B72A1D Q28655456-EBDDAE73-0D91-4A0B-A163-B0FAEF480164 Q33649823-61322F54-331A-4A44-9E44-50BCCF524CA6 Q33683147-D7AA7CC6-0A3F-4FD1-8C00-E39710A27A87 Q33733991-67AFE455-863A-42A8-A1CA-8AA1EDD96494 Q33741185-4C7FCB9D-73E6-46FA-AB80-D3D71C6F82BE Q33774051-661916CF-7E85-49AD-8464-72F4605FED23 Q33814552-1E360EFE-FE0E-4ED6-8021-2120098EBE93 Q33905828-3309E810-B30A-4140-81E0-79C3027BBDD0 Q33991690-273ACB1F-DFA1-4FC7-8D2E-C1FEA48B76FF Q34039414-952F7F65-5BDB-4016-B2FC-C646549B7AC3 Q34086900-D2109E87-33BF-4200-9FE3-C66F3462A1E9 Q34188396-FD4D1032-FE37-4D3B-A9D4-612288888476 Q34208548-148EBC7D-D112-4509-8BD6-EA84E00F38B8 Q34302149-990602F5-B820-4563-B131-E9EF7AFFDD59 Q34449010-E4B94EFA-BF4B-45CA-B56E-A2B7C8E26C1E Q34469733-081646A8-D43C-4962-9CC5-CEC9835EDBA6 Q34488985-5C7AD4B5-6797-40AC-9007-E6B860858402 Q34499844-7FDA85D1-1D93-4FC1-B2AF-0AC81A85FBF0 Q34687279-7418D623-CEB8-44F6-B278-B88A12B1C1A4 Q34956047-76C6A40C-4F77-437E-8671-F80B5478A305 Q35051166-325C13DA-E547-4DF8-B651-133922C559F8 Q35057879-F3C201B2-E093-4886-810E-2F5AC75D2853 Q35556455-7BC1CCCD-E153-4999-B88B-ABD7DF6A988E Q35639764-91E97A64-3D4A-4D7B-B96C-6509DC3C2065 Q35653799-E78FCDEF-BD8C-41E5-B56A-16537D41E711 Q35982475-8C3C01A1-F956-4341-8FD1-CFB1E18FAAB3 Q36269159-F16F3042-A4B3-44A8-99AB-4D7B56793458 Q36282739-E3A48D5E-B534-48B0-BAF1-4D66CA7732F2 Q36347787-E9D84A78-EF57-4846-B72C-4E65C9C0831A Q36473616-A1EB3BCC-B66E-4245-AEA4-45183B8E72D4 Q36734546-8DC8A635-567F-4F56-99D7-154EB282BDDE Q37432505-B7489498-826A-4F97-AF6C-96DD73C7A17C Q37494793-3A36CA55-0493-4750-816E-0533D3908266 Q37645066-FBF39A09-17E7-46EB-9E38-AAF1BC0C44DD Q37718254-76EBF0F2-83CB-4EFE-9801-41BE78635FD7

P2860

A role for ceramide in driving cancer cell resistance to doxorubicin.

http://www.wikidata.org/entity/Q40017408

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

A role for ceramide in driving cancer cell resistance to doxorubicin.

@en

type

label

A role for ceramide in driving cancer cell resistance to doxorubicin.

@en

prefLabel

A role for ceramide in driving cancer cell resistance to doxorubicin.

@en

P1433

Q40017408-F8BCDFDD-4DFD-407C-BA1E-C5EDCFE45DFA

P1476

Q40017408-E7C584DD-BB14-41AB-A82F-697E0B413EB1

P2093

Q40017408-229E541B-CDC0-478E-8AC4-B468555DE20E

Q40017408-2877F338-5170-46DA-BECA-2AAFF186E6A3

Q40017408-2A07F66B-8803-4B8B-8B67-D16DF732B805

Q40017408-2B992EDE-7444-4B01-AF4D-1DD06D03B92E

Q40017408-42BD7FA1-D841-407E-B3E6-44AB265C6B00

Q40017408-42DFF7A3-8E37-4D65-9C39-4871A2357CA7

Q40017408-48AD2EA3-C3D4-453D-9102-8FBC49509C16

Q40017408-5BAAE95D-73D6-4FEE-B169-4F9EF2DF252E

Q40017408-733B5415-82CB-49EC-A7DE-B810B6B925F1

Q40017408-F79FEB56-0958-426C-A009-ACE56E5AE9DB

P304

Q40017408-B8AF3FC5-0C86-40AB-9B53-0D588604AE1F

P31

Q40017408-8E24FF68-30F3-44F9-B25A-0A49C4222B51

P356

Q40017408-C45924D8-1E92-4412-9B8B-2950594EEFD1

P407

Q40017408-13BD620E-5968-4079-9DCD-F4643C10C78C

P433

Q40017408-8373675B-4454-46FD-BB85-173C5449146E

P478

Q40017408-20F77714-F190-4DF7-B24B-6F47A885F96A

P50

Q40017408-3A31FAF4-6AC5-47D8-A27A-8462DC42B9B9

Q40017408-6312234F-C727-4897-870D-2B112B6B9476

P577

Q40017408-EDF0ADD6-B00E-4F40-BA69-9CC558540BF9

P698

Q40017408-3D03C1FA-539A-48C9-ADFB-D7017B4BEF3B

P356

P1433

P1476

A role for ceramide in driving cancer cell resistance to doxorubicin

@en

P2093

Armando E Giuliano

http://www.w3.org/2001/XMLSchema#string

David P Consoli

http://www.w3.org/2001/XMLSchema#string

Dongmei Yin

http://www.w3.org/2001/XMLSchema#string

Gauri Anand Patwardhan

http://www.w3.org/2001/XMLSchema#string

Jing Yuan Yu

http://www.w3.org/2001/XMLSchema#string

Myles C Cabot

http://www.w3.org/2001/XMLSchema#string

S Michal Jazwinski

http://www.w3.org/2001/XMLSchema#string

Vineet Gupta

http://www.w3.org/2001/XMLSchema#string

Walter M Holleran

http://www.w3.org/2001/XMLSchema#string

Yoshio Hirabayashi

http://www.w3.org/2001/XMLSchema#string

P304

2541-2551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1096/FJ.07-092981

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Valerie Gouaze-Andersson

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18245173

http://www.w3.org/2001/XMLSchema#string